Sidley Austin is advising GlycoMimetics, Inc. on the transaction, and Gibson, Dunn & Crutcher is advising Crescent Biopharma, Inc. GlycoMimetics, Inc. (NASDAQ: GLYC) announced it has...
GlycoMimetics’ Acquisition of Crescent Biopharma
ARCA Biopharma’s Merger with Oruka Therapeutics
Wilson Sonsini Goodrich & Rosati is advising ARCA biopharma, Inc. on the transaction, while Gibson, Dunn & Crutcher is advising Oruka Therapeutics and Cooley is advising...
XOMA’s Acquisition of Kinnate Biopharma
XOMA was represented by Gibson, Dunn & Crutcher LLP. XOMA Corporation (NASDAQ: XOMA) announced it has entered an agreement to acquire Kinnate Biopharma Inc. (NASDAQ: KNTE) for a...
Magenta Therapeutics’ Merger with Dianthus Therapeutics
Gibson, Dunn & Crutcher LLP acted for Dianthus Therapeutics, Inc. on its merger with Magenta Therapeutics, Inc., assisted by Goodwin Procter. Magenta Therapeutics, Inc. (Nasdaq: MGTA) and Dianthus Therapeutics,...
Mondelez International Holdings Netherlands B.V.’s €300 Million Exchangeable Bonds Offering
Gibson, Dunn & Crutcher and Loyens & Loeff have advised Mondelez International Holdings Netherlands B.V., while White & Case LLP has advised the Sole Global Coordinator...